Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency (Q38832928)

6 September 2017

1 reference

title

Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency (English)

1 reference

Joanna Chorostowska-Wynimko

6 September 2017

1 reference

series ordinal

1

object named as

Joanna Chorostowska-Wynimko

1 reference

PubMed ID

27172295

6 September 2017

language of work or name

English

0 references

publication date

12 May 2016

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

6 September 2017

1 reference

6 September 2017

13

1 reference

6 September 2017

807-815

1 reference

6 September 2017

6

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

6 September 2017

start time

12 May 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

The discovery of α1-antitrypsin and its role in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Small-airway obstruction and emphysema in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Defining disease modification in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Development of disease-modifying treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Alpha-1 antitrypsin augmentation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

The delayed-start study design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Endpoints for trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Disease-modifying trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Elastin degradation: an effective biomarker in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Changes in forced expiratory volume in 1 second over time in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Lessons from ECLIPSE: a review of COPD biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

One-year change in health status and subsequent outcomes in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Modifying the course of chronic obstructive pulmonary disease: looking beyond the FEV1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Predictors of mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Progression parameters for emphysema: a clinical investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Variation of densitometry on computed tomography in COPD--influence of different software tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Predictors of mortality in alpha1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Effects of all-trans-retinoic acid in promoting alveolar repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412555.2016.1178224

10.1080/15412555.2016.1178224

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27172295